Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 17, Number 10—October 2011

CME ACTIVITY

Invasive Non-Aspergillus Mold Infections in Transplant Recipients, United States, 2001–2006

Benjamin J. ParkComments to Author , Peter G. Pappas, Kathleen A. Wannemuehler, Barbara D. Alexander, Elias J. Anaissie, David R. Andes, John W. Baddley, Janice M. Brown, Lisa M. Brumble, Alison G. Freifeld, Susan Hadley, Loreen Herwaldt, James I. Ito, Carol A. Kauffman, G. Marshall Lyon, Kieren A. Marr, Vicki A. Morrison, Genovefa Papanicolaou, Thomas F. Patterson, Trish M. Perl, Mindy G. Schuster, Randall Walker, John R. Wingard, Thomas J. Walsh, and Dimitrios P. Kontoyiannis

Author affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA (B.J. Park, K.A. Wannemuehler); University of Alabama at Birmingham Medical Center, Birmingham, Alabama, USA (P.G. Pappas, J.W. Baddley); Duke University Medical Center, Durham, North Carolina, USA (B.D. Alexander); University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA (E.J. Anaissie); University of Wisconsin–Madison, Madison, Wisconsin, USA (D.R. Andes); Stanford University School of Medicine, Stanford, California, USA (J.M. Brown); Mayo Clinic, Jacksonville, Florida, USA (L.M. Brumble); University of Nebraska Medical Center, Omaha, Nebraska, USA (A.G. Freifeld); Tufts Medical Center, Boston, Massachusetts, USA (S. Hadley); University of Iowa Hospital, Iowa City, Iowa, USA (L. Herwaldt); City of Hope National Medical Center, Duarte, California, USA (J.I. Ito); University of Michigan, Ann Arbor, Michigan, USA (C.A. Kauffman); Veterans Affairs Ann Arbor Healthcare System–Medicine, Ann Arbor (C.A. Kauffman); Emory University School of Medicine, Atlanta (G.M. Lyon); Johns Hopkins Medical Institutions, Baltimore, Maryland, USA (K.A. Marr, T.M. Perl); Fred Hutchinson Cancer Research Center, Seattle, Washington, USA (K.A. Marr); University of Minnesota, Minneapolis, Minnesota, USA (V.A. Morrison); Veterans Affairs Medical Center, Minneapolis (V.A. Morrison); Memorial Sloan Kettering Cancer Center, New York, New York, USA (G. Papanicolaou); University of Texas Health Sciences Center, San Antonio, Texas, USA (T.F. Patterson); South Texas Veterans Healthcare System, San Antonio (T.F. Patterson); Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA (M.G. Schuster); Mayo Clinic, Rochester, Minnesota, USA (R. Walker); University of Florida, Gainesville, Florida, USA (J.R. Wingard); National Institutes of Health, Bethesda, Maryland, USA (T.J. Walsh); MD Anderson Cancer Center, Houston, Texas, USA (D.P. Kontoyiannis)

Main Article

Table 4

Antifungal medications received before and after diagnosis of invasive mold infection, TRANSNET data, United States, 2001–2006*

Antifungal drug Mucorales, no. (%), n = 105 Fusarium spp., no. (%), n = 37 Scedosporium spp., no. (%), n = 27 Total, no. (%),
N = 169
Received before diagnosis
Amphotericin B† 7 (6.7) 5 (13.5) 3 (11.1) 15 (8.9)
Fluconazole 35 (33.3) 17 (45.9) 5 (18.5) 57 (33.7)
Itraconazole 13 (12.4) 4 (10.8) 8 (29.6) 25 (14.8)
Voriconazole 47 (44.8) 10 (27.0) 3 (11.1) 60 (35.5)
Caspofungin 18 (17.1) 3 (8.1) 3 (11.1) 24 (14.2)
Posaconazole
0
1 (2.7)
0
1 (0.6)
Received after diagnosis
Amphotericin B† 82 (78.1) 19 (51.4) 9 (33.3) 110 (65.1)
Fluconazole 4 (3.8) 0 0 4 (2.4)
Itraconazole 10 (9.5) 2 (5.4) 8 (29.6) 20 (11.8)
Voriconazole 39 (37.1) 20 (54.1) 15 (55.6) 74 (43.8)
Caspofungin 26 (24.8) 12 (32.4) 11 (40.7) 49 (29.0)
Posaconazole 24 (22.9) 3 (8.1) 3 (11.1) 30 (17.8)

*TRANSNET, Transplant-Associated Infection Surveillance Network. Numbers do not total 100% because of concomitant receipt of multiple antifungal agents.
†Any amphotericin B formulation.

*TRANSNET, Transplant-Associated Infection Surveillance Network. Numbers do not total 100% because of concomitant receipt of multiple antifungal agents.
†Any amphotericin B formulation.

Main Article

TOP